| Detailed information |
|---|
| CancerLivER ID | 2125 |
| Biomarker | prostaglandin E1 |
| Biomarker Name/Symbol (given in Publication) | prostaglandin E1 |
| Biomolecule | Metabolites |
| Subject | Mice |
| Degree of Validity | Non-invasive candidate biomarkers in the clinical application of AFLD for health management; but not validated in human patient cohorts |
| Experimental Condition | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled |
| Cancer type | Alcoholic fatty liver disease (AFLD) |
| Regulation | Upregulated in AFLD |
| Level of significance | |
| Source | Serum |
| PMID | 24171385 |
| Type of Biomarker | Potential Predictive * |
| Pathway | arachidonic acid pathway, amino acid metabolism |
| Cohort | Six-week-old male C57BL/6 (B6) mice (BioLASCO Taiwan Co.) were maintained at the animal housing facility of the Institute of Food Science and Technology, National Taiwan University |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Mice, alcoholic fatty liver disease (AFLD) |
| Year of Publication | 2013 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |